Safety of synthetic trans‐resveratrol as a novel food pursuant to Regulation (EC) No 258/97
2016; Wiley; Volume: 14; Issue: 1 Linguagem: Inglês
10.2903/j.efsa.2016.4368
ISSN1831-4732
Tópico(s)Insect and Pesticide Research
ResumoEFSA JournalVolume 14, Issue 1 4368 OpinionOpen Access Safety of synthetic trans-resveratrol as a novel food pursuant to Regulation (EC) No 258/97 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)Search for more papers by this author EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)Search for more papers by this author First published: 12 January 2016 https://doi.org/10.2903/j.efsa.2016.4368Citations: 25 Panel members: Jean Louis Bresson, Barbara Burlingame, Tara Dean, Susan Fairweather-Tait, Marina Heinonen, Karen Ildico Hirsch-Ernst, Inge Mangelsdorf, Harry McArdle, Androniki Naska, Monika Neuhäuser-Berthold, Grażyna Nowicka, Kristina Pentieva, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Daniel Tomé, Dominique Turck, Hendrik Van Loveren, Marco Vinceti and Peter Willatts. Correspondence: [email protected] Acknowledgement: The Panel wishes to thank the members of the Working Group on Novel Foods: Tara Dean, Karl-Heinz Engel, Marina Heinonen, Inge Mangelsdorf, Rosangela Marchelli, Harry McArdle, Monika Neuhäuser-Berthold, Annette Pöting, Morten Poulsen, Yolanda Sanz, Josef Schlatter and Hendrik Van Loveren for the preparatory work on this scientific opinion. Adoption date: 11 December 2015 Published date: 12 January 2016 Question number: EFSA-Q-2014-00232 On request from: European Commission following an application by DSM Nutritional Products Ltd AboutPDF ToolsExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked for an opinion on the safety of synthetic trans-resveratrol as a novel food with a purity of ≥99% (w/w). The Panel considers that the information provided on the composition and specifications of the novel food is sufficient. The applicant intends to market the novel food as a food supplement in capsule or tablet form at daily doses up to 150 mg/day. The Panel considers that resveratrol does not have a nutritionally relevant role in the human diet and that the consumption of the novel food is not nutritionally disadvantageous. In accordance with the EFSA Scientific opinion on genotoxicity testing strategies, the Panel considers that the negative in vivo genotoxicity assay is sufficient to rule out the concern based on the positive in vitro chromosomal aberration tests. Reduced body weight gain is seen consistently in animal studies. On the basis of the BMDL05 of 344 mg/kg body weight (bw) per day derived from body weight data of female rats in a subchronic toxicity study and the intended intake of 150 mg/day, the margin of exposure is 172. For pregnant rats, it is below 62. Considering the weight of evidence, the Panel concludes that the intended intake level of 150 mg/day for adults does not raise safety concerns. The Panel notes that diarrhoea or other gastrointestinal symptoms were reported in four uncontrolled intervention studies at doses of 1 g resveratrol/day or higher. The Panel considers that the metabolite trans-resveratrol sulfate could inhibit CYP enzymes in humans and may interact with medicines which are mainly metabolised by CYP2C9. The Panel concludes that the novel food, synthetic trans-resveratrol, is safe under the proposed conditions of use. References Almeida L, Vaz-da-Silva M, Falcao A, Soares E, Costa R, Loureiro AI, Fernandes-Lopes C, Rocha JF, Nunes T, Wright L, Soares-da-Silva P, 2009. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers, Molecular Nutrition & Food Research 53(Suppl 1): S7– S15. Ashby J, Tinwell H, Pennie W, Brooks AN, Lefevre PA, Beresford N, Sumpter JP, 1999. Partial and weak oestrogenicity of the red wine constituent resveratrol: consideration of its superagonist activity in MCF-7 cells and its suggested cardiovascular protective effects, Journal of Applied Toxicology 19(1): 39– 45. Beck M and Bruchlen M, 2007. Excretion balance and tissue distribution after oral administration of 14C-resveratrol to rats. Internal DSM report. DSM Nutritional Products Ltd., Basel. Report Number: 2500434. Beck M, Elste V, Bruchlen M, 2007. Plasma kinetics and exposure after oral administration of resveratrol in rats. Internal DSM report. DSM Nutritional Products Ltd., Basel. Report Number: 2500433. Beck M, Mair P, Bruchlen M, Loechleiter F, 2006. In vitro absorption and metabolism studies with 14C-resveratrol. Internal DSM report. DSM Nutritional Products Ltd., Basel. Report Number: 2500288. Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM, 2001. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Research. 2001 Oct 15; 61(20): 7456– 63. Bhatt, JK, Thomas S, Nanjan MJ, 2012. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutrition Research, 32, 537– 541. Boocock DJ, Faust GES, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP, Brenner DE, 2007. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiology Biomarkers & Prevention 16(6): 1246– 1252. Brasnyo P, Molnar GA, Mohas M, Marko L, Laczy B, Cseh J, Mikolas E, Szijarto IA, Merei A, Halmai R, Meszaros LG, Sumegi B, Wittmann I, 2011. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients, British Journal of Nutrition 106(3): 383– 389. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward WP, Gescher AJ, Brenner DE, 2010. Repeat dose study of the cancer chemopreventive agent in healthy volunteers: safety, pharmacokinetics and effect on the insulin-like growth factor axis. Cancer Research 70: 9003– 9011. Cantos E, Espín JC, Tomás-Barberán FA, 2002. Varietal differences among the polyphenol profiles of seven table grape cultivars studied by LC-DAD-MS-MS. Journal of Agricultural and Food Chemistry 50: 5691– 5696. Chételat A, Beck M, Wolz E, 2003. Resveratrol: Micronucleus test in rat bone marrow – oral administration (gavage) - Study No.:479M03, DSM Nutritional Products Ltd. (former Roche Vitamins AG), Basel. Report Number: 1000543. Chow HHS, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS, 2010. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study, Cancer Prevention Research 3(9): 1168– 1175. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL, 2010. Resveratrol bioavailability and toxicity in humans. Molecular Nutrition & Food Research, Jan; 54(1): 7– 16. Cottart CH, Nivet-Antoine V, Beaudeux JL, 2014. Review and recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Molecular Nutrition & Food Research, Jan; 58(1): 7– 21. Crandall JP, Oram V, Trandafirescu G, Reid M, Kishore P, Hawkins M, Cohen HW, Barzilai N, 2012. Pilot Study of Resveratrol in Older Adults with Impaired Glucose Tolerance, Journal of Gerontology: Medical Sciences 67, 1307– 1312. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS, 2004. Resveratrol associated renal toxicity, Toxicology Science 82(2): 614– 619. Czeczot H, Podsiad M, Skrzycki M, Stochmal A, Oleszek W, 2003. Evaluation of the mutagenic activity of phenolics from the bark of Yucca schidigera Roezl. Acta Poloniae Pharmaceutica 60: 357– 362. De Groote, D., Van Belleghem, K., Deviere, J., Van Brussel, W, Mukaneza A, Amininejad L, 2012. Effect of the intake of resveratrol, resveratrol phosphate, and catechin-rich grape seed extract on markers of oxidative stress and gene expression in adult obese subjects. Annals of Nutrition and Metabolism, 2012, 61, 15– 24. Detampel P, Beck M, Krähenbühl S, Huwyler J, 2012. Drug interaction potential of resveratrol. Drug Metabolism Reviews 44(3): 253– 265. Dunn R, 2007. Resveratrol in vitro mammalian chromosome aberration test in human lymphocytes. DSM Nutritional Products Ltd., Basel, Switzerland. DNO 0014/0625795. Huntingdon Life Sciences Limited, 2 April 2007. Edwards JA, Scase K, Burger D, Hofmann P, Wilson J, 2007a. Resveratrol (Ro 40–6302/000), 3-month oral toxicity study followed by a 4-week recovery period in Wistar rats Study performed at Laboratory: Notox B.V., Hambakenwetering 7, 5231 DD'sHertogenbosch, The Netherlands; Study Project No. 452453. Edwards J, Stannard D, Burger D, Hofmann P, 2007b. Resveratrol embryo-fetal study in the CD rat by dietary administration. DSM Nutritional Products Ltd., Basel, Switzerland. Report Number: 2500210. Edwards J and Sokolowsky A, 2009. Resveratrol Photomutagenicity Reverse Mutation Assay, Harlan Cytotest Cell Research GmbH No. 1231902, DSM internal report, RDR No. 2000902. Edwards JA, Beck M, Riegger C, Bausch J, 2011. Safety of resveratrol with examples for high purity, trans-resveratrol, resVida. Annals of the New York Academy of Science 1215: 131– 137. EFSA Scientific Committee (Scientific Committee), 2011. Scientific opinion on genotoxicity testing strategies applicable to food and feed safety assessment. EFSA Journal 2011; 9(9): 2379, 69 pp. doi:10.2903/j.efsa.2011.2379 Elliott PJ, Walpole S, Morelli L, Lambert PD, Lunsmann W, Westphal CH, Lavu S, 2009. Resveratrol/SRT501. Monography. Drugs of the Future 34(4): 291– 295. Freyberger A, Hartmann E, Hildebrand H, Krötlinger F, 2001. Differential response of immature rat uterine tissue to ethinylestradiol and the red wine constituent resveratrol, Archives of Toxicology 74(11): 709– 715. Gescher A, Steward WP, Brown K, 2013. Resveratrol in the management of human cancer: how strong is the clinical evidence? Annals of the New York Academy of Science 1290: 12– 20. Ghanim H, Sia CL, Abuaysheh S, Korzeniewski K, Patnaik P, Marumganti A, Chaudhuri A, Dandona P, 2010. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol, Journal of Clinical Endocrinology and Metabolism 95(9): E1– E8. Ghanim, H., Sia, C. L., Korzeniewski, K., Lohano, T. Abuaysheh S, Marumganti A, Chaudhuri A, Dandona P, 2011. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high carbohydrate meal. Journal of Clinical Endocrinology and Metabolism, 96, 1409– 1414. Goldberg DM, Karumanchiri A, Ng E, Yan J, Diamandis, EP, Soleas GJ, 1995. Direct gas chromatographic-mass spectrometric method to assay cis-resveratrol in wines: preliminary survey of its concentration in commercial wines. Journal of Agriculture and Food Chemistry 43: 1245– 1250. Horn TL, Cwik MJ, Morrissey RL, Kapetanovic I, Crowell JA, Booth TD, McCormick DL, 2007. Oncogenicity evaluation of resveratrol in p53(±) (p53 knockout) mice. Food and Chemical Toxicology 45(1): 55– 63. Howells LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, Hegarty B, Brown K, Steward WP, Gescher AJ, 2011. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics, Cancer Prevention Research (Phila) 4(9): 1419– 25. Hynes G, 2007. Resveratrol rat micronucleus test. DSM Nutritional Products Ltd., Basel, Switzerland. DNO 0015/063572. Huntingdon Life Sciences Limited, 25 May 2007. Johnson WD, Morrissey RL, Usborne AL., Kapetanovic I, Crowell JA, Muzzio M, McCormick DL, 2011. Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity. Food and Chemical Toxicology 49(12): 3319– 3337. Kennedy DO, Wightman EL, Reay JL, Lietz G, Okello EJ, Wilde A, Haskell CF, 2010. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation, American Journal of Clinical Nutrition 91(6): 1590– 1597. la Porte C, Voduc N, Zhang G, Seguin I, Tardiff D, Singhal N, Cameron DW, 2010. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects, Clinical Pharmacokinetics 49(7): 449– 454. Lamuela-Raventós RM, Romero-Pérez AI, Waterhouse AL., de la Torre-Boronat MC, 1995. Direct HPLC analysis of cis- and trans-resveratrol and piceid isomers in Spanish red Vitis vinifera wines. Journal of Agriculture and Food Chemistry 43: 281– 283. Mair P, Beck M, Bruchlen M, Colletto M, Radspieler A, Stoll R, Baldinger T, Furrer C, Elste V, 2006. Metabolism of resveratrol in rats. Poster presentation at the 17th International Mass Spectrometry Conference, Prague, August 26-September 1, 2006. DSM Nutritional Products Ltd., Basel. Report Number: 2500253. Nguyen, A. V., Martinez, M., Stamos, M. J., Moyer MP, Planutis K, Hope C, Holcombe RF, 2009. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Management Research. 1, 25– 37. Norkus EP, 2007. Study Report (No LS-07–01): A study to determine the levels of resveratrol in the blood following ingestion of a synthetic trans-resveratrol and a plant-derived source of resveratrol by human subjects. Our Lady of Mercy Medical Center, Bronx, NY. (Aug 28, 2007). Nunes, T., Almeida, L., Rocha, J. F., Falcao, A, Fernandes-Lopes C, Loureiro AI, Wright L, Vaz-da-Silva M, Soares-da-Silva P, 2009. Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. Journal of Clinical Pharmacology. 49, 1477– 1482. Ortuño J, Covas MI, Farre M, Pujadas M, Fitó M, Khymenets O, Andrés-Lacueva C, Roset P, Joglar J, Lamuela-Raventós RM, de la Torre R, 2010. Matrix effects on the bioavailability of resveratrol in humans. Food Chemistry. 2010: 120(4): 1123– 1130 Patel, K. R., Scott, E., Brown, V. A., Gescher, A., Steward W P, Brown K, 2011. Clinical trials of resveratrol. Annals of the New York Academy of Science, 1215, 161– 169. Paulo L, Domingues F, Queiroz JA, Gallardo E, 2011. Development and validation of an analytical method for the determination of trans- and cis-resveratrol in wine: analysis of its contents in 186 Portuguese red wines. Journal of Agricultural and Food Chemistry 59: 2157– 2168. Poulsen, M. M., Vestergaard, P. F., Clasen, B. F., Radko, Y, Christensen LP, Stødkilde-Jørgensen H, Møller N, Jessen N, Pedersen SB, Jørgensen JO, 2013. High-Dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 4, 1186– 1195. Romero-Pérez AI, Ibern-Gómez M, Lamuela-Raventós RM, de la Torre-Boronat MC, 1999. Piceid, the major resveratrol derivative in grape juices. Journal of Agricultural and Food Chemistry 47: 1533– 1536. Schmitt E, Lehmann L, Metzler M, Stopper H, 2002. Hormonal and genotoxic activity of resveratrol, Toxicology Letters 136(2): 133– 142. Sokolowski A, 2012. Salmonella Typhimurium Reverse Mutation Assay, Harlan CCR GmbH, Study No. 1465800. 28 September, 2012. Tennant D, 2012. Resveratrol assessment of intake: intended use and background diet. Report. DSM Nutritional Products Europe Ltd. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MK, Kunz I, Schrauwen-Hinderling VB, Blaak EE, Auwerx J, Schrauwen P, 2011. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metabolism. 2; 14(5): 612– 22. Tome-Carneiro, J., Gonzalvez, M., Larrosa, M., Garcia-Almagro, F. J., Avilés-Plaza F, Parra S, Yáñez-Gascón MJ, Ruiz-Ros JA, García-Conesa MT, Tomás-Barberán FA, Espín JC, 2012a. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Molecular Nutrition & Food Research, 56, 810– 821. Tome-Carneiro, J., Gonzalvez, M., Larrosa, M., Yanez-Gascon, M. J., García-Almagro FJ, Ruiz-Ros JA, García-Conesa MT, Tomás-Barberán FA, Espín JC, 2012b. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. American Journal of Cardiology, 110, 356– 363. Turner RT, Evans GL, Zhang M, Maran A, Sibonga JD, 1999. Is resveratrol an estrogen agonist in growing rats? Endocrinology 140(1): 50– 54. Vaz-da-Silva, M., Loureiro, A. I., Falcao, A., Nunes, T, Rocha JF, Fernandes-Lopes C, Soares E, Wright L, Almeida L, Soares-da-Silva P, 2008. Effect of food on the pharmacokinetic profile of trans-resveratrol. International journal of clinical pharmacology and therapeutics, 46, 564– 570. Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK, 2004. High absorption but very low bioavailability of oral resveratrol in humans, Drug Metabolism Disposition 32(12): 1377– 1382. Williams LD, Burdock GA, Edwards JA, Beck M, Bausch J, 2009. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol 47: 2170– 2182. Wolz E, Scase K, 2005. Resveratrol (Ro 40–6302/000): 28-day oral dietary study in the rat. Study performed at NOTOX B.V., Hambakenwetering 7, 5231 DD's-Hertogenbosch, The Netherlands; Study Number 418218 Wong RHX, Howe PRC, Buckley JD, Coates AM, Kunz I, Berry NM, 2010. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutrition, Metabolism & Cardiovascular Diseases, 2011, 21, 851– 856. Yoshino, J., Conte, C., Fontana, L., Mittendorfer, B, Imai S, Schechtman KB, Gu C, Kunz I, Rossi Fanelli F, Patterson BW, Klein S, 2012. Resveratrol supplementation does not improve metabolic function in non-obese women with normal glucose tolerance. Cell Metabolism, 2012, 16, 658– 664. Zamora-Ros R, Andres-Lacueva C, Lamuela-Raventós R, Berenguer T, Jakszyn P, Martínez C, Sánchez MJ, Navarro C, Chirlaque MD, Tormo M-J, Quirós JR, Amiano P, Dorronsoro M, Larrañage N, Barricarte A, Ardanaz E, González C, 2008. Concentrations of resveratrol and derivatives in foods and estimation of dietary intake in a Spanish population: European Prospective Investigation into Cancer and Nutrition (EPIC)-Spain cohort. British Journal of Nutrition 100: 188– 196. Zamora-Ros, R., Urpi-Sarda, M., Lamuela-Raventos, R. M., Martinez-Gonzalez, M. A, Salas-Salvadó J, Arós F, Fitó M, Lapetra J, Estruch R, Andres-Lacueva C, PREDIMED Study Investigators, 2012. High urinary levels of resveratrol metabolites are associated with a reduction in the prevalence of cardiovascular risk factors in high-risk patients. Pharmacology Research. 2012, 65, 615– 620. Zhu, W., Qin, W., Zhang, K., Rottinghaus, G. E. Chen Y C, Kliethermes B, Sauter E R, 2012. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutrition and Cancer, 64, 393– 400. Citing Literature Volume14, Issue1January 20164368 ReferencesRelatedInformation
Referência(s)